SUBSCRIBE
SUBSCRIBE
News   Policy

Basilea Pharmaceutica Announces Filing of New Drug Submission in Canada for Alitretinoin

December 21, 2007 | 
1 min read

Basel, Switzerland, December 21st, 2007 - Basilea Pharmaceutica Ltd. (SWX: BSLN) announced today the filing of a New Drug Submission (NDS) for alitretinoin with the Therapeutic Products Directorate of Health Canada.

Regulatory Europe
MORE ON THIS TOPIC
Donald Trump behind a podium
Government
Lilly, Pfizer Execs Sing Optimistic Tune on Incoming Admin After Trump Dinner
December 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Art collage, hands and scales of justice. The concept of the law of the judge.
Legal
Former CytoDyn Officials Found Guilty of Securities Fraud
December 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
RSV
Moderna’s RSV Vaccines Run Into Safety Roadblock
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac